BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-637 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-637\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06934889-2320@assetmemo.bio
DTSTAMP:20261121T005432Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:ABBV-637: Phase 1 readout est. (NCT06934889)
DESCRIPTION:ABBV-637\, phase 1.\nStudy: Study of ABBV-637 or ABBV-155 With 
 ERAS-801 for People With Glioblastoma\nEstimated primary completion: April
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/abbv-637#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06934889
URL:https://assetmemo.bio/drug/abbv-637#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
